• 1
    Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K. Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494502.
  • 2
    Ackman M, Graham M, Hui C, Tsuyuki R. Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting. Can J Cardiol 2006; 22: 12058.
  • 3
    Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008; 178: 41320.
  • 4
    Pfisterer M, Brunner-La Rocca HP, Buser PT et al. The BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 258491.
  • 5
    King SB 3rd, Smith SJ, Hirshfeld JJ et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:26195.
  • 6
    Silber S, Albertsson P, Avilés F et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 80447.
  • 7
    Savi P, Zachayus J, Delesque-Touchard N et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 2006; 103: 1106974.
  • 8
    Kim K, Park P, Hong S, Park J. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 23642.
  • 9
    Mega J, Close S, Wiviott S et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 35462.
  • 10
    Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 36375.
  • 11
    Pham C, Regal R, Bostwick T, Knauf K. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006; 40: 12616.
  • 12
    Bhatt D, Scheiman J, Abraham N et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:150217.
  • 13
    Li X, Andersson T, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 8217.
  • 14
    Lim P, Goh K, Wong B. CYP2C19 genotype and the PPIs--focus on rabeprazole. J Gastroenterol Hepatol 2005; 20(Suppl): S228.
  • 15
    Siller-Matula J, Spiel A, Lang I, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148. e1-5.
  • 16
    Gilard M, Arnaud B, Le Gal G, Abgrall J, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 25089.
  • 17
    Gilard M, Arnaud B, Cornily J et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 25660.
  • 18
    Juurlink D, Gomes T, Ko D et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 7138.
  • 19
    Kreutz R, Stanek E, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30: 78796.
  • 20
    O’Donoghue M, Braunwald E, Antman E et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 98997.
  • 21
    Bhatt D, Cryer B, Contant C et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 190917.
  • 22
    Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 9219.
  • 23
    Brunner-La Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28: 71925.
  • 24
    Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007;28:252538.
  • 25
    Cutlip D, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 234451.
  • 26
    Ho P, Maddox T, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 93744.
  • 27
    Hulot J, Collet J, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 13443.